| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2a data readout example | Phase 1/2a | — | Subscribe to access the data. | RNA-Based Therapies | Rare Diseases | ||
Phase 1/2a data readout example | Phase 1/2a | — | Subscribe to access the data. | RNA-Based Therapies | Rare Diseases | ||
Phase 1/2a data readout example | Phase 1/2a | — | Subscribe to access the data. | RNA-Based Therapies | Rare Diseases |
Recent Updates
Recently added Catalysts
Korro Bio, Inc.$14.56
+0.26 (+1.82%)
D 26Pipeline Score Richly Valued Pharma · Commercial
Market Cap
167.45 M
EPS
-11.68
P/E Ratio
-
Value Trade
1.42 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
12.95 M
Operating CF
-16.07 M
Total Assets
183.62 M
Total Liabilities
63.99 M
Equity
119.63 M
D/E Ratio
12,345
5.55 %
Week
-15.26 %
1 Month
0.43 %
3 Month
92.86 %
6 Month
-97.38 %
5 Year
-97.93 %
All Time
Cash Data
Cash Position
113.97 M
Monthly Burn
5.36 M
Runway
19.4 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
233.78 K
52 Week Range
5.20 - 55.89
% held by Insiders
30.14 %
% held by Institutions
59 %
Enterprise Value
95.36 M
Total Shares
14.41 M
Short %
16.16 %
Float Shares
10.55 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Korro Bio, Inc.
256Total events
7Upcoming
50Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 7
Event history 249
Q3 2026
◆NDA SubmissionKRRO-121Regulatory Filing
Regulatory filing for KRRO-121 expected in 2H 2026
Hyperammonemiasource ↗
Jun 4, 2026
◆Oral PresentationPresentation
Korro to present at 2026 Jefferies Global Healthcare Conference
May 25, 2026
◆Poster PresentationPresentation
Poster at EASL: Uncontrolled Ammonia is Associated with Increased Healthcare Resource Utilization in Hepatic Encephalopathy
Hepatic Encephalopathysource ↗
May 20, 2026
◆Oral PresentationPresentation
2026 RBC Capital Markets Global Healthcare Conference Fireside Chat
May 19, 2026
◆Oral PresentationPresentation
HCW 4th Annual BioConnect Nasdaq Investor Conference Fireside Chat
May 19, 2026
▲Development Candidate NominationKRRO-111Preclinical
KRRO-111 selected as development candidate for AATD
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
May 15, 2026
◆Oral PresentationPresentation
Oral presentation at ASGCT: GalNAc-conjugated RNA editing oligonucleotide achieves >90% editing of pathogenic SERPINA1 transcripts, restoring AAT function in AATD models
Alpha-1 Antitrypsin Deficiencysource ↗
May 14, 2026
◆Oral PresentationKRRO-121Presentation
Oral presentation at ASGCT: KRRO-121 demonstrates robust ammonia clearance in preclinical models
hyperammonemiasource ↗
May 14, 2026
◆Oral PresentationPresentation
Podium presentation at TIDES USA: Precision RNA editing at scale: platform innovations generating product candidates
May 13, 2026
◆Poster PresentationPresentation
Poster at ASGCT: Novel triplet chemistries informed by structural biology expand OPERA platform capabilities
May 12, 2026
◆Poster PresentationPresentation
Poster at ASGCT: RNA Editing of TARDBP reduces TDP-43 aggregation while restoring nuclear localization and splicing function in ALS disease models
ALSsource ↗
Drug Pipeline Intelligence
D26
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 27%
Micro Cap (rank 666 of 911)
Percentile RankKorro Bio, Inc. faces pipeline headwinds (26/100), with $18M risk-adjusted pipeline value, led by KRRO-110 in Alpha-1 Anti-trypsin Deficiency (Phase 1).
Showing 0 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
FX-322 | Presbycusis (Age-Related Hearing Loss) | Phase 1b | 2021-05-13 | no significant treatment effect with FX-322 administration compared to placebo Read More | Frequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results Data From Recent FX-322 Clinical Readouts, Including New Data from Phase 1b Study in Presbycusis (Age-Related Hearing Loss Read More | |
FX-322 | Presbycusis (Age-Related Hearing Loss) | Phase 1b | 2021-05-13 | no significant treatment effect with FX-322 administration compared to placebo Read More | Frequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results Data From Recent FX-322 Clinical Readouts, Including New Data from Phase 1b Study in Presbycusis (Age-Related Hearing Loss Read More | |
FX-322 | Presbycusis (Age-Related Hearing Loss) | Phase 1b | 2021-05-13 | no significant treatment effect with FX-322 administration compared to placebo Read More | Frequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results Data From Recent FX-322 Clinical Readouts, Including New Data from Phase 1b Study in Presbycusis (Age-Related Hearing Loss Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KRRO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KRRO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KRRO▲ +1.8%today
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Korro Bio, Inc. has announced the grant of non-statutory stock options to seven newly hired employees as part of its 2026 Inducement Plan. The options, which have varying exercise prices and vesting schedules, were approved by the company's Compensation Committee. This move is aligned with Nasdaq Listing Rule 5635(c)(4) and reflects Korro's commitment to attracting talent in the biopharmaceutical sector.
Read more →KRRO▲ +11.6%on this news
Korro to Present at the 2026 Jefferies Global Healthcare Conference
Korro Bio, Inc. announced that its CEO, Dr. Ram Aiyar, will present at the 2026 Jefferies Global Healthcare Conference in New York. The presentation is scheduled for June 4, 2026. Korro is focused on developing genetic medicines using its OPERA platform, which enables precise RNA editing for therapeutic applications.
Read more →KRRO▼ -8.2%on this news
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Korro Bio has selected KRRO-111 as a development candidate for treating Alpha-1 Antitrypsin Deficiency (AATD). This GalNAc-conjugated oligonucleotide has shown promising preclinical results, achieving over 90% editing of the SERPINA1 transcript and significant reduction of pathogenic Z-protein. The company aims to advance KRRO-111 into clinical trials, highlighting its potential as a best-in-class therapy.
Read more →KRRO▼ -8.1%on this newsshared move
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro Bio, Inc. has announced the granting of a non-statutory stock option to a newly hired employee as part of its 2026 Inducement Plan, compliant with Nasdaq Listing Rule 5635(c)(4). The stock option allows the employee to purchase 3,000 shares at an exercise price of $11.20 each, with a vesting schedule extending over four years. Korro continues to develop its innovative OPERA platform, aimed at creating genetic therapies for a range of diseases. This strategic hiring move bolsters its workforce in pursuit of advancing biopharmaceutical solutions.
Read more →KRROKorro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Korro Bio reported its first quarter 2026 financial results, highlighting significant advancements in its RNA editing platform. The company is on track for a regulatory filing of its lead program, KRRO-121, aimed at treating hyperammonemia in patients with urea cycle disorders. Additionally, Korro achieved over 90% in vivo RNA editing in its GalNac-conjugated program for alpha-1 antitrypsin deficiency, supported by an $85 million private placement to fund ongoing research.
Read more →KRRO▲ +6%on this newsshared move
Korro to Participate in Upcoming May 2026 Investor Conferences
Korro, a biopharmaceutical company, announced its participation in two upcoming investor conferences in May 2026. The events will feature key executives discussing the company's innovative OPERA platform, which is designed for developing genetic medicines. This platform aims to provide precise RNA editing for therapeutic applications, enhancing the potential for effective treatments.
Read more →KRROKorro to Participate in Upcoming Investor Conferences
Korro, a biopharmaceutical company, announced its participation in two upcoming investor conferences. The events include a fireside chat at the HCW 4th Annual BioConnect Nasdaq Investor Conference on May 19, 2026, and another at the 2026 RBC Capital Markets Global Healthcare Conference on May 20, 2026. The company aims to leverage its OPERA platform to develop innovative genetic medicines.
Read more →KRROKorro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
Korro Bio, Inc. will present its RNA editing technology at several upcoming scientific conferences, including ASGCT and EASL. Key presentations will focus on the efficacy of their oligonucleotide delivery system and its potential applications in treating hyperammonemia and Alpha-1 Antitrypsin deficiency. The company aims to leverage its innovative platform to advance genetic medicines.
Read more →KRRO▲ +11.3%on this news
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Korro Bio, Inc. reported its financial results for Q4 and full year 2025, highlighting a cash position of $85.2 million and increased collaboration revenue. However, the company faced a net loss of $117.3 million, largely due to impairment charges. Korro aims to leverage its RNA editing platform for future growth and has secured funding through a recent private placement.
Read more →KRRO▲ +10%on this news
Korro Announces Oversubscribed $85 Million Private Placement
Korro Bio, Inc. announced an oversubscribed $85 million private placement led by Venrock Healthcare Capital Partners. The funds will support the company's RNA editing programs, including clinical data for KRRO-121 and a GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency. The financing is expected to extend Korro's cash runway into 2028.
Read more →KRROKorro to Present at the TD Cowen 46th Annual Health Care Conference
Korro Bio, Inc. will present at the TD Cowen 46th Annual Health Care Conference in Boston from March 2-4, 2026. CEO Ram Aiyar is scheduled to speak on March 3 at 11:10 a.m. ET. The company focuses on RNA editing for genetic medicines aimed at treating rare and prevalent diseases.
Read more →KRROForward-Looking Statements and Disclaimers Forward-Looking Statements Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Securities Litigat
Korro Bio, Inc. (ticker: KRRO) is advancing KRRO-121, a potential first-in-class treatment aimed at addressing ammonia control in patients with urea cycle disorders. The company anticipates filing for regulatory approval in the second half of 2026, highlighting KRRO-121's innovative approach through RNA editing to enhance the function of glutamine synthetase. This treatment could significantly benefit patients struggling with high ammonia levels due to conditions like hepatic encephalopathy. However, the development is subject to typical biopharmaceutical risks, including the uncertainties surrounding clinical trial outcomes and regulatory approval processes.
Read more →KRROKorro to Host Virtual Analyst Day on January 27, 2026
Korro Bio, Inc. announced a virtual Analyst Day scheduled for January 27, 2026, featuring discussions on KRRO-121, aimed at treating hyperammonemia. The event will include insights from company management, a clinical hepatologist, and a caregiver, highlighting the unmet needs in ammonia-driven diseases. Korro plans to file for regulatory approval for KRRO-121 in the second half of 2026.
Read more →KRROCONCEPT PROGRAM / INDICATION DELIVERY DISCOVERY PRECLINICAL DEVELOPMENT PHASE 1 PHASE 2 PHASE 3 Stabilize Protein KRRO-121 Hyperammonemia GalNAc (SC) Repair Pathogenic Variant AATD GalNAc (SC) Allosteric Activator Longev
Korro Bio, Inc. (KRRO) has provided an update on its pipeline and future development plans, emphasizing its approach to RNA editing and drug delivery targeting AATD and hyperammonemia. Despite highlighting promising programs, the company faces uncertainties associated with biopharmaceutical development, including regulatory approvals and clinical trial outcomes. The forward-looking statements suggest caution as Korro navigates these risks, compounded by the recent termination of its clinical trial for KRRO-110. The organization aims to make significant progress with its TDP43 pipeline in the coming years.
Read more →KRRO▲ +7.8%on this news
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference
Korro Bio, Inc. (Nasdaq: KRRO) announced that its CEO Dr. Ram Aiyar will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. Alongside him, other executives including COO Todd Chappell and CSO Dr. Loic Vincent will participate in the event. This presentation will highlight Korro's advancements in RNA editing technologies aimed at treating various diseases. A live webcast of the presentation will be available on Korro's Investor Relations website.
Read more →KRRO▼ -79.3%on this news
Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs
Korro Bio, Inc. reported its third quarter financial results and provided updates on its KRRO-110 program for Alpha-1 Antitrypsin Deficiency (AATD). The Phase 1/2a REWRITE trial showed that KRRO-110 produced functional M-AAT protein, although not at projected levels. The company is also advancing KRRO-121 for hyperammonemia and restructuring to focus on clinical data generation while extending its cash runway into 2027.
Read more →KRRO▲ +17.2%on this news· ran to +48% by day 3
Korro to Participate in Upcoming Investor and Scientific Conferences
Korro Bio, Inc. announced its participation in several investor and scientific conferences throughout September 2025. Key executives will engage in 1x1 meetings and discussions at events such as Citi's Biopharma Conference and the RNA Leaders USA Congress. The company aims to showcase its advancements in RNA editing therapies for various diseases.
Read more →KRRO▲ +6.2%on this news· ran to +35% by day 3
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates
Korro Bio, Inc. reported its second quarter 2025 financial results, highlighting progress in its Phase 1/2a REWRITE clinical trial for KRRO-110. The company has completed dosing in over 80% of planned healthy volunteers, with no serious adverse events observed. The European Medicines Agency granted Orphan Drug Designation for KRRO-110, aimed at treating Alpha-1 Antitrypsin Deficiency. Despite a net loss increase, Korro maintains a strong cash position to support ongoing operations.
Read more →KRROKorro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
Korro Bio, Inc. has been granted orphan drug designation by the European Medicines Agency for KRRO-110, aimed at treating Alpha-1 Antitrypsin Deficiency (AATD). This designation underscores the need for innovative therapies for AATD patients. KRRO-110, which has demonstrated promising preclinical results, is currently undergoing evaluation in a Phase 1/2a clinical trial, with interim data anticipated in late 2025.
Read more →KRRO▼ -5.8%on this news
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates — Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the seco
Korro Bio, Inc. reported its financial results for the first quarter of 2025 and provided key business updates. The company remains focused on the interim readout from its Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency, expected in the second half of 2025. As part of a restructuring initiative, Korro announced a 20% workforce reduction to streamline operations while aiming to extend its financial runway into 2027. The financial report revealed a cash position of $139 million but also noted an increase in net losses compared to the previous year.
Read more →KRRO▼ -8.4%on this news
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
Korro Bio, Inc. has appointed Dr. Loïc Vincent as Chief Scientific Officer, bringing over 20 years of drug development experience. His role will be crucial as Korro advances its pipeline, including the Phase 1/2a REWRITE clinical study for Alpha-1 Antitrypsin Deficiency. Dr. Vincent's background includes leadership positions at Affini-T Therapeutics and Takeda.
Read more →KRROKorro Reports Full Year 2024 Financial Results and Provides Business Updates
Korro Bio, Inc. reported its full-year 2024 financial results, highlighting the initiation of the Phase 1/2a REWRITE clinical study for KRRO-110 and a collaboration with Novo Nordisk that generated revenue. The company anticipates interim data from the study in the second half of 2025 and plans to announce a second development candidate by the end of 2025. Despite a net loss increase, Korro's cash reserves are expected to fund operations into 2026.
Read more →KRROKRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
Korro Bio, Inc. announced that the FDA has granted orphan drug designation to KRRO-110 for treating Alpha-1 Antitrypsin Deficiency (AATD). This investigational medicine aims to address both liver and lung issues associated with the condition. The drug is currently in the Phase 1/2a REWRITE clinical study, with interim results expected in late 2025.
Read more →KRROKorro to Present at the TD Cowen 45th Annual Health Care Conference
Korro Bio, Inc. announced that its CEO, Ram Aiyar, will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025. The presentation will focus on Korro's advancements in RNA editing for genetic medicines. Additionally, COO Todd Chappell will engage in one-on-one investor meetings during the event. A live webcast will be available for attendees.
Read more →KRRO▲ +8.2%on this news
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update KRRO-110 is the first product candidate from Korro s proprietary RN
Korro Bio has initiated dosing for its REWRITE Phase 1/2a study of KRRO-110, targeting Alpha-1 Antitrypsin Deficiency (AATD). The study aims to evaluate the safety and tolerability of KRRO-110 in participants, including those with the PiZZ genotype. Administered through RNA editing technology, KRRO-110 seeks to restore normal M-AAT protein levels to address both lung and liver issues associated with AATD. Interim results are expected in late 2025, signaling a key advancement in Korro's clinical pipeline.
Read more →KRRO▼ -7.2%on this newsshared move
Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Korro Bio, Inc. has announced that its CEO, Ram Aiyar, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The company specializes in developing innovative genetic medicines through RNA editing technology, targeting both rare and prevalent diseases. Alongside Aiyar, other executive team members will also participate in the conference, which is an important platform for healthcare organizations. A live webcast of the presentation will be available for investors and stakeholders.
Read more →KRRO▲ +7.7%on this news
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency — REWRITE study will evaluate the safety, tolerability, phar
Korro Bio, Inc. has received approval from the Australian HREC and TGA to start a Phase 1/2a study of KRRO-110 for Alpha-1 Antitrypsin Deficiency. This REWRITE study will assess the drug's safety, tolerability, and pharmacokinetics in up to 64 participants, including healthy adults and AATD patients with the PiZZ genotype. The first patient is expected to be dosed in Q1 2025, with interim results anticipated by the second half of 2025. KRRO-110 aims to address serious complications from AATD by utilizing RNA editing technology.
Read more →KRRO▼ -9.7%on this news
Korro to Present at the Jefferies London Healthcare Conference
Korro Bio, Inc. announced that its CEO, Ram Aiyar, alongside other key executives, will present at the Jefferies London Healthcare Conference on November 19, 2024. The presentation will focus on Korro’s novel RNA editing platform aimed at developing genetic medicines for various diseases. Attendees will be able to access a live webcast of the presentation on the company’s website, followed by a replay available for 30 days. Korro continues to explore the potential of RNA editing as a more precise alternative to traditional genetic therapies.
Read more →KRRO▼ -11.4%on this news· ran to -35% by day 3shared move
Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates — Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) &
Korro Bio, Inc. has reported its financial results for Q3 2024, revealing a net loss of $21 million. The company has submitted a regulatory filing for the first-in-human clinical study of KRRO-110, aimed at treating alpha-1 antitrypsin deficiency. A strong cash position, expected to last into the second half of 2026, supports its ongoing projects, including a collaboration with Novo Nordisk to explore RNA editing therapies. Additionally, Korro has formed a Clinical Advisory Board to guide the development of KRRO-110 as it progresses toward initial dosing in early 2025.
Read more →KRROKorro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board — Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD)
Korro Bio, Inc. has announced the regulatory submission for a Phase 1/2 clinical trial of its drug KRRO-110, aimed at treating Alpha-1 Antitrypsin Deficiency (AATD). This marks a pivotal transition to a clinical-stage company, highlighted by the formation of a Clinical Advisory Board comprising renowned experts. Pending necessary approvals, the first dosing is anticipated in early 2025, with preliminary data expected later that year. KRRO-110 employs an innovative RNA editing mechanism that aims to provide significant therapeutic benefits in lung and liver function.
Read more →KRROKorro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society
Korro Bio, Inc. has announced its participation at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal, where it will deliver one oral and two poster presentations. Venkat Krishnamurthy will present on KRRO-110, aimed at treating alpha-1 antitrypsin deficiency. The presentations reflect Korro's commitment to advancing RNA editing technologies for genetic diseases, highlighting its proprietary platform and focus on precise RNA modulation.
Read more →KRROKorro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates Partnership leverages Korro's proprietary OPERA TM platform to enable its oligonucleotide-directed RNA edits into two undisclosed
Korro Bio has announced a collaboration with Novo Nordisk aimed at developing two therapeutic candidates for cardiometabolic diseases utilizing Korro's OPERA platform. The partnership involves a total deal value of up to $530 million, which includes various milestone payments and tiered royalties. The collaboration seeks to leverage both companies' strengths in RNA editing and drug development to create new genetic therapies. Korro plans to advance the programs through preclinical development, with further clinical advancement potentially led by Novo Nordisk.
Read more →KRROKorro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
Korro Bio, Inc. has appointed Dr. Katharine Knobil as an Independent Director to its Board of Directors, effective immediately, while David Lucchino has resigned. Dr. Knobil brings over 25 years of experience in clinical development and regulatory affairs from various prominent roles. The company expresses confidence that her expertise will be invaluable in advancing its innovative RNA editing therapies. Lucchino's contributions during Korro's transition to a public company are acknowledged as significant, and he is thanked by Korro's management.
Read more →KRROKorro to Participate in Upcoming September Investor and Scientific Conferences
Korro Bio, Inc. (Nasdaq: KRRO) announced its participation in several upcoming investor and scientific conferences in September 2024. Key executives will showcase the company's innovative OPERA™ RNA editing platform and its potential benefits for treating rare and widespread diseases. The involvement in these conferences reflects Korro's commitment to transparency and engagement with stakeholders, while also positioning itself as a leader in genetic medicine. Additionally, the company aims to leverage existing knowledge in RNA editing to improve patient outcomes.
Read more →KRROKorro Reports Second Quarter 2024 Financial Results and Provides Business Updates — Regulatory filing of first-in-human (FIH) trial of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) anticipated in
Korro Bio, Inc. reported its second quarter 2024 financial results, highlighting progress on its lead candidate KRRO-110 for treating alpha-1 antitrypsin deficiency (AATD). The company anticipates filing for a first-in-human trial in the second half of 2024, supported by promising preclinical data. Korro ended the quarter with $187.8 million in cash, ensuring financial backing through the second half of 2026. However, the company also noted an increase in net losses and R&D expenses compared to the previous year.
Read more →KRROKorro Joins the Russell 2000 , Russell 3000 , and Russell Microcap Indexes
Korro Bio, Inc. has announced its inclusion in the Russell 2000, Russell 3000, and Russell Microcap Indexes as part of the annual reconstitution. This inclusion is effective from July 1, 2024, and signifies enhanced visibility for the company among investors. CEO Dr. Ram Aiyar expressed optimism about advancing their drug candidate KRRO-110 for Alpha-1 Antitrypsin Deficiency, with plans for regulatory filing and interim data readout scheduled for the coming years. This move aims to support the company's efforts in fulfilling its commitment to stakeholders.
Read more →KRROKorro to Participate in Upcoming June Investor and Scientific Conferences
Korro Bio, Inc. (Nasdaq: KRRO) will participate in several upcoming conferences, providing updates on its RNA editing therapies. CEO Ram Aiyar will present at the Jefferies Global Healthcare Conference, while CMO Kemi Olugemo will discuss the company's lead candidate for treating Alpha-1 Antitrypsin Deficiency at the Alpha-1 Foundation National Conference. Additionally, Dr. Venkat Krishnamurthy will address key strategies for RNA editing therapeutics at the 5th Annual RNA Editing Summit, further showcasing Korro's proprietary OPERA platform.
Read more →KRROKorro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
Korro Bio, Inc. presented new preclinical data for its candidate KRRO-110 at the ATS 2024 International Conference, showcasing a significant editing efficiency of about 60% and considerable increases in alpha-1 antitrypsin levels in a mouse model. The data indicated sustained efficacy past previous benchmarks, with potential future human studies anticipated by late 2024. The findings suggest KRRO-110 might effectively address Alpha-1 Antitrypsin Deficiency, a condition currently lacking adequate treatment options.
Read more →KRROKorro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer — On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-
Korro Bio reported its financial results for the first quarter of 2024 and announced the appointment of Kemi Olugemo as Chief Medical Officer. The company is advancing its candidate KRRO-110, targeting regulatory filing for the drug in patients with Alpha-1 Antitrypsin Deficiency in the second half of 2024. With $70 million from a recent private placement, Korro has a strengthened cash position to support ongoing development and anticipated clinical trials.
Read more →KRROKorro Announces $70 Million Private Placement Financing led by Deep Track Capital with participation from other leading healthcare investors Pro-forma cash and cash equivalents of approximately $236 million before fees a
Korro Bio, Inc. announced that it has entered into a subscription agreement to conduct a private placement financing, anticipated to yield approximately $70 million. The company plans to utilize the proceeds to advance its Phase 1/2 clinical trial of KRRO-110 in AATD patients and to further develop its pipeline focused on RNA editing technology. With this financing, Korro's pro forma cash and equivalents are projected to be around $236 million, providing substantial runway for upcoming projects. The PIPE is expected to close on April 22, 2024, subject to standard closing conditions.
Read more →KRROKorro Announces $70 Million Private Placement
Korro Bio, Inc. announced a private placement to raise approximately $70 million, aimed at supporting the development of its RNA editing therapies. The financing, led by Deep Track Capital, is expected to close on April 22, 2024. Korro has a robust cash position of about $236 million, which will fund a First-in-Human study for KRRO-110 aimed at treating Alpha-1 Antitrypsin Deficiency patients by 2024, alongside progress in other pipeline programs. The funds will also assist in covering corporate expenses and advancing clinical trials into the market.
Read more →KRRO▲ +18.4%on this newsshared move
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress On track for regulatory filing for First-in-Human study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the secon
Korro Bio, Inc. reported its financial results for the full year 2023, underlining significant progress in its pipeline and operations. The company highlighted major achievements, including the selection of KRRO-110 as a candidate for treating Alpha-1 Antitrypsin Deficiency (AATD) and a strong cash position expected to fund operations through 2026. Despite reporting a significant net loss, Korro's CEO expressed optimism for 2024, anticipating multiple milestones, including a regulatory filing for KRRO-110 planned for the latter half of the year.
Read more →KRRO▼ -6.1%on this news
Korro to Present at the TD Cowen 44th Annual Health Care Conference
Korro Bio, Inc. (Nasdaq: KRRO) announced its participation in the TD Cowen 44th Annual Health Care Conference, where CEO Ram Aiyar will present. The event is scheduled for March 4, 2024, in Boston, Massachusetts, and will also feature CFO Vineet Agarwal and CSO Steve Colletti. Attendees can access a live webcast of the presentation, which will be available for replay for 30 days afterward. Korro is known for its efforts in developing genetic medicines through an RNA editing platform.
Read more →KRRO▼ -6%on this news
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio
Korro Bio, Inc. has announced promising data for KRRO-110, a treatment aimed at Alpha-1 Antitrypsin Deficiency (AATD), which showed high levels of functional protein secretion in preclinical models. The company is making strides in RNA editing technology, demonstrating significant editing capabilities and potential for durable therapeutic effects. Korro is preparing for a regulatory filing in the second half of 2024, with an interim clinical readout expected in 2025. The CEO emphasized the commitment to delivering innovative therapies for conditions with significant unmet medical needs.
Read more →KRROto its Current Report on Form 8-K filed with the SEC on
Korro Bio, Inc. has filed a Current Report on Form 8-K with the SEC, detailing its forward-looking statements regarding RNA editing technology and the drug candidate KRRO-110 aimed at treating alpha-1 antitrypsin deficiency. The report highlights the company's strong financial health with a cash runway extending into 2026, which is intended to support clinical trials and regulatory filings. Despite the positive outlook, Korro acknowledges the inherent risks and uncertainties associated with biopharmaceutical development. The company aims to leverage its innovative technology and robust pipeline to impact rare and common diseases effectively.
Read more →KRROKorro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Korro Bio, Inc. announced that CEO Ram Aiyar will present at the upcoming J.P. Morgan Healthcare Conference, discussing preclinical data for its candidate KRRO-110 targeting Alpha-1 Antitrypsin Deficiency. Alongside him, CFO Vineet Agarwal and CSO Steve Colletti will participate in the event. The company highlights its RNA editing platform as a novel approach to developing genetic therapies. Korro is preparing for a potential regulatory filing for KRRO-110 in the second half of 2024.
Read more →KRRO▼ -14.7%on this news
Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Korro Bio, Inc. has announced the selection of KRRO-110 as its first development candidate for treating Alpha-1 Antitrypsin Deficiency (AATD). The candidate, developed using Korro's proprietary OPERA platform, shows promising preclinical data, including high editing efficiency and the ability to repair misfolded proteins. The company plans to file for regulatory approval in the second half of 2024, highlighting the therapy's potential to meet significant unmet needs for AATD patients. This announcement marks a crucial milestone in Korro's mission to develop innovative genetic medicines for rare diseases.
Read more →KRRO▲ +6.5%on this news· ran to +31% by day 3
Korro Bio Appoints Dr. Rachel Meyers to Board of Directors
Korro Bio, Inc. has appointed Dr. Rachel Meyers to its Board of Directors. Dr. Meyers brings over 20 years of experience in life sciences, particularly in RNA-based medicines. Her past roles include Chief Scientific Officer at Faze Medicines and significant positions at Alnylam Pharmaceuticals. The company's focus is on developing genetic medicines utilizing its RNA editing platform, which aims to provide advancements in treating rare and prevalent diseases.
Read more →KRROUPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of a
Korro Bio, Inc. has successfully announced the completion of its merger with Frequency Therapeutics, following a private placement of $117 million. The new company will operate under the name Korro Bio and trade on the Nasdaq under the symbol KRRO starting November 6, 2023. Korro aims to leverage its RNA editing platform to develop new genetic therapies, focusing on advancing its lead product candidate in Alpha-1 Antitrypsin Deficiency (AATD). The transaction has positioned the company to move forward with multiple potentially valuable programs in its pipeline.
Read more →KRROKorro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
Korro Bio, Inc. has completed its merger with Frequency Therapeutics and raised $117 million in a private placement. The combined company will focus on RNA editing programs and expects to utilize approximately $170 million in cash reserves to fund operations through 2026. Key milestones include advancing their lead candidate for Alpha-1 antitrypsin deficiency into clinical trials. Korro's stock will begin trading under the ticker KRRO on November 6, 2023.
Read more →KRROKorro Bio Announces Appointment of Tim Pearson to Board of Directors Upon Closing of the Proposed Merger and Promotion of Todd Chappell to Chief Operating Officer
Korro Bio has announced the appointment of Tim Pearson as an independent Board member upon the closing of its proposed merger with Frequency Therapeutics, expected in Q4 2023, alongside Todd Chappell's promotion to Chief Operating Officer. The merger aims to bolster Korro's genetic medicine capabilities, particularly in RNA editing for diseases. Both leaders bring substantial industry experience, which is deemed critical for the company's transition to becoming a public entity. However, the approval process from Frequency's stockholders poses a risk to the merger timeline.
Read more →KRROFrequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results
Frequency Therapeutics announced its business updates and financial results for Q2 2023, highlighting a definitive merger agreement with Korro Bio, expected to close by Q4 2023. The merger aims to focus on advancing RNA editing programs under the ticker KRRO. Financially, the company significantly reduced expenses compared to the previous year, but reported a net loss of $10.8 million for the quarter. Additionally, Frequency continues to look for strategic options regarding its remyelination program for multiple sclerosis.
Read more →KRROKorro Bio and Frequency Therapeutics Announce Merger Agreement Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio s wholly owned portfolio of RNA editing programs Lead program is a
Korro Bio and Frequency Therapeutics announced a merger to form a Nasdaq-listed genetic medicines company, primarily focusing on Korro's RNA editing programs. The combined entity is projected to have a cash balance of around $170 million, facilitating milestones through 2026. Korro's lead program targets alpha-1 antitrypsin deficiency and has demonstrated encouraging preclinical outcomes. The merger requires shareholder approval and other customary conditions before completion, expected by the fourth quarter of 2023.
Read more →KRROFrequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results
Frequency Therapeutics announced promising business updates and financial results for Q1 2023, highlighting advancements in their remyelination program for multiple sclerosis (MS). The company has demonstrated progress in preclinical studies, showing improvements in MRI measurements and potential for a best-in-class treatment. Despite a reported net loss of $19.5 million, Frequency believes its financial restructuring will support continued development and clinical trials, extending its runway into 2025.
Read more →KRROFrequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results
Frequency Therapeutics has reported its business updates and financial results for 2022, revealing a focus shift towards developing a remyelination program for multiple sclerosis due to the discontinuation of its hearing restoration programs. The company announced a robust cash position that should support operations into early 2025, along with significant cost-saving measures through personnel reductions. Remyelination efforts show promising preclinical results, but the failure of recent clinical trials presents challenges going forward.
Read more →KRROForward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presenta
Frequency Therapeutics has made significant advancements in developing a first-in-class remyelination therapeutic for Multiple Sclerosis, with plans to enter clinical trials in H1 2024. Their proprietary Progenitor Cell Activation (PCA) platform has shown promise by outperforming well-studied comparator compounds in preclinical studies. However, the company faces ongoing challenges, including a substantial financial loss and the unproven nature of its PCA technology. As they discontinue their hearing programs to focus on remyelination, Frequency aims to leverage its cash reserves to navigate future developmental milestones.
Read more →KRROFrequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results Enrollment Completed for Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss; Readout Expected in Q1 2023 Com
Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results Enrollment Completed for Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss; Readout Expected in Q1 2023 Company on Track for Q4 Clinical Trial Start of its Second He
Read more →KRROPioneering a New Category in Regenerative Medicine Frequency Therapeutics Corporate Presentation September 2022 Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements withi
Frequency Therapeutics Corporate Presentation September 2022 Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within the meaning of the dependence on the development of FX-322; the unproven approach of the PCA Private Securi
Read more →KRROFrequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results Q1 2023 Readout Planned for FX-322-208 Phase 2b Sensorineural Hearing Loss Study, with Enrollment Completion Anticipated in Q3 Q4
Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results Q1 2023 Readout Planned for FX-322-208 Phase 2b Sensorineural Hearing Loss Study, with Enrollment Completion Anticipated in Q3 Q4 Enrollment Start Planned for Phase 1b Study of Second Hea
Read more →KRROFrequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results FX-322-208 Phase 2b Study in Individuals with Acquired Sensorineural Hearing Loss Remains on Track for a Readout in Q4 2022 or Q1
Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results FX-322-208 Phase 2b Study in Individuals with Acquired Sensorineural Hearing Loss Remains on Track for a Readout in Q4 2022 or Q1 2023 Reports Cash and Cash Equivalents of $124.8M, Providi
Read more →KRROPioneering a New Category in Regenerative Medicine Frequency Therapeutics Corporate Presentation April 2022 Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within th
Frequency Therapeutics Corporate Presentation April 2022 Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within the meaning of the process of clinical drug development and regulatory approval; limited experience Private Sec
Read more →KRROPioneering a New Category in Regenerative Medicine Frequency Therapeutics Corporate Presentation March 2022 Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within th
Frequency Therapeutics Corporate Presentation March 2022 Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within the meaning of the process of clinical drug development and regulatory approval; limited experience Private Sec
Read more →KRROFrequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results Company Reports Steady Enrollment for FX-322-208 Phase 2b Study in Individuals with Sudden and Noise-Induce
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results Company Reports Steady Enrollment for FX-322-208 Phase 2b Study in Individuals with Sudden and Noise-Induced Sensorineural Hearing Loss; Topline Results Anticipated i
Read more →KRROPioneering a New Category in Regenerative Medicine Frequency Therapeutics Corporate Presentation January 2022 Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within
Frequency Therapeutics Corporate Presentation January 2022 Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within the meaning of the process of clinical drug development and regulatory approval; limited experience Private S
Read more →KRROPioneering a New Category in Regenerative Medicine Frequency Therapeutics Corporate Presentation December 2021 Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within
Frequency Therapeutics Corporate Presentation December 2021 Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within the meaning of the process of clinical drug development and regulatory approval; limited experience Private
Read more →KRROFrequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results Enrollment Underway for FX-322-208 Phase 2b Study in Subjects with Sudden and Noise-Induced Sensorineural Hearing Loss; Aligns wit
Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results Enrollment Underway for FX-322-208 Phase 2b Study in Subjects with Sudden and Noise-Induced Sensorineural Hearing Loss; Aligns with FDA on Speech Perception as Primary Endpoint for FX-322 S
Read more →KRROPioneering a New Category in Regenerative Medicine Frequency Therapeutics Corporate Presentation Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within the meaning o
Frequency Therapeutics Corporate Presentation Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within the meaning of the process of clinical drug development and regulatory approval; limited experience Private Securities Lit
Read more →KRROLEADING A NEW CATEGORY IN REGENERATIVE MEDICINE Advancing Novel Approaches to Hearing Restoration Corporate Overview September 2021 Copyright Frequency Therapeutics, Inc. 1 Forward-Looking Statements and Other Disclaimer
Novel Approaches to Hearing Restoration Corporate Overview September 2021 Copyright Frequency Therapeutics, Inc. 1Exhibit 99.1 LEADING A NEW CATEGORY IN REGENERATIVE MEDICINE Advancing Novel Approaches to Hearing Restoration Corporate Overview September 2021 Copyright Frequency
Read more →KRROThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical
August 2021 Exhibit 99.2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-
Read more →KRROFrequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results Data From Recent FX-322 Clinical Readouts, Including New Data from Phase 1b Study in Presbycusis (Age-Related Hearing Loss
Frequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results Data From Recent FX-322 Clinical Readouts, Including New Data from Phase 1b Study in Presbycusis (Age-Related Hearing Loss), Further Clarify Acquired Sensorineural Hearing Loss Targ
Read more →KRROFrequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2020 Financial Results Recent FX-322 Study Readouts Support Single-Dose Administration as Part of Future Trial Designs; Company Pl
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2020 Financial Results Recent FX-322 Study Readouts Support Single-Dose Administration as Part of Future Trial Designs; Company Planning Additional Single Injection Studies Results from
Read more →KRROFrequency Therapeutics Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322 Results Published in Leading Peer-Reviewed Otolaryngology Journ
Frequency Therapeutics Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322 Results Published in Leading Peer-Reviewed Otolaryngology Journal, Otology & Neurotology Statistically Significant Impr
Read more →KRROREIMAGINING THE TREATMENT OF HEARING LOSS Corporate Overview January 2021 Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within the approval for and commercializing
REIMAGINING THE TREATMENT OF HEARING LOSS Corporate Overview January 2021 Forward-Looking Statements and Other Disclaimers This presentation contains forward-looking statements within the approval for and commercializing product candidates; the results of meaning of the Private
Read more →KRROFrequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer
Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer Mass., December 1, 2020 Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body s innate biology to repair or reverse damage caused by a bro
Read more →KRROFREQUENCY THERAPEUTICS PROVIDES BUSINESS UPDATES AND REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS Day-90 Analysis of FX-322 Phase 2a Study for Acquired Sensorineural Hearing Loss (SNHL) Planned for Late Q1 2021; End of S
FREQUENCY THERAPEUTICS PROVIDES BUSINESS UPDATES AND REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS Day-90 Analysis of FX-322 Phase 2a Study for Acquired Sensorineural Hearing Loss (SNHL) Planned for Late Q1 2021; End of Study Readout Planned in Late Q2 2021 Commenced Phase 1b St
Read more →KRROFORWARD-LOOKING STATEMENTS AND OTHER DISCLAIMERS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presenta
Frequency Therapeutics Corporate Overview October 2020 Exhibit 99.1 FORWARD-LOOKING STATEMENTS AND OTHER DISCLAIMERS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in th
Read more →KRROFrequency Therapeutics Appoints Cynthia Feldmann to its Board of Directors
Frequency Therapeutics Appoints Cynthia Feldmann to its Board of Directors WOBURN, Mass., Sept. 25, 2020 Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body s innate biology to repair or reverse damage caused by a b
Read more →KRROFREQUENCY THERAPEUTICS PROVIDES BUSINESS UPDATES AND REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS Expects to Complete Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss by Early Q4 2020; Study Readout An
FREQUENCY THERAPEUTICS PROVIDES BUSINESS UPDATES AND REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS Expects to Complete Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss by Early Q4 2020; Study Readout Anticipated in Q2 2021 Recently Announced Clinical Data Show
Read more →KRROFREQUENCY THERAPEUTICS PROVIDES BUSINESS UPDATES AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS Phase 2a Study of FX-322 for Sensorineural Hearing Loss Continues Enrollment at Multiple Sites Shares Top-Line Data from E
FREQUENCY THERAPEUTICS PROVIDES BUSINESS UPDATES AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS Phase 2a Study of FX-322 for Sensorineural Hearing Loss Continues Enrollment at Multiple Sites Shares Top-Line Data from Exploratory Clinical Study Confirming Delivery of FX-322 t
Read more →KRROA letter from David L. Lucchino Chief Executive Officer Dear fellow shareholders, This past year was one of tremendous progress for Frequency Therapeutics, and I could not be more proud to lead an organization that may r
A letter from David L. Lucchino Chief Executive Officer Dear fellow shareholders, This past year was one of tremendous progress for Frequency Therapeutics, and I could not be more proud to lead an organization that may redefine the landscape for regenerative therapeutics and
Read more →KRROFrequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2019 Financial Results Phase 2a Study of FX-322 for Sensorineural Hearing Loss Remains Ongoing Strong Cash Position at End of 2019
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2019 Financial Results Phase 2a Study of FX-322 for Sensorineural Hearing Loss Remains Ongoing Strong Cash Position at End of 2019 Providing Runway into 2022; Potential for Meaningful FX-
Read more →KRROFrequency Therapeutics Provides Business Updates and Reports Third Quarter 2019 Financial Results Initiated FX-322 Phase 2a clinical study for sensorineural hearing loss Granted FDA Fast Track designation for FX-322 Comp
Frequency Therapeutics Provides Business Updates and Reports Third Quarter 2019 Financial Results Initiated FX-322 Phase 2a clinical study for sensorineural hearing loss Granted FDA Fast Track designation for FX-322 Completed an $88.6 million initial public offering in October
Read more →Competitive Position
How KRRO ranks across every disease it competes inCompetitive Position is a premium feature
See how KRRO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial